Navigation Links
FDA Approves Hologic's Makena™ (Formerly Referred to as Gestiva™) Pharmaceutical
Date:2/4/2011

BEDFORD, Mass., Feb. 4, 2011 /PRNewswire/ -- Hologic, Inc. (Hologic or the Company) (Nasdaq: HOLX), a leading developer, manufacturer and supplier of premium diagnostics products, medical imaging systems and surgical products dedicated to serving the healthcare needs of women, announced today the U.S. Food and Drug Administration (FDA) has approved Hologic's pharmaceutical named Makena™ (hydroxyprogesterone caproate injection), formerly known as Gestiva™. Per the terms of an asset purchase agreement (the Agreement) between Hologic and KV Pharmaceutical Company (KV), Hologic will transfer the Company's Makena assets (the Transfer) to KV upon the satisfaction of certain conditions, including receipt of a $12.5 million cash payment from KV. Transfer is expected to be completed by February 11, 2011.

Under the Agreement, Hologic has already received $79.5 million in cash payments from KV, plus reimbursement of Hologic's expenses relating to Makena. In addition to the $12.5 million cash payment expected to be received by February 11, 2011, KV is required to make additional payments to Hologic totaling $107.5 million over a period not to exceed 30 months, which will result in a total purchase price of $199.5 million.

About Hologic, Inc.Hologic, Inc. is a leading developer, manufacturer and supplier of premium diagnostics products, medical imaging systems and surgical products dedicated to serving the healthcare needs of women. Hologic's core business units are focused on breast health, diagnostics, GYN surgical, and skeletal health. Hologic provides a comprehensive suite of technologies with products for mammography and breast biopsy, breast magnetic resonance imaging, radiation treatment for early-stage breast cancer, cervical cancer screening, treatment for menorrhagia and uterine fibroids, permanent contraception, osteoporosis assessment, preterm birth risk assessment, mini C-arm for extremity imaging and molecular diagnostic products including HPV and reagents for a variety of DNA and RNA analysis applications. For more information, visit www.hologic.com.

Hologic, Gestiva, Makena, and associated logos are trademarks and/or registered trademarks of Hologic, Inc. and/or its subsidiaries in the United States and/or other countries.

Forward Looking DisclaimerThis News Release contains forward-looking information that involves known and unknown risks and uncertainties. The Company cannot assure that KV will have the necessary cash funding available to make payments under this Agreement as they come due. The risks and uncertainties included above are not exhaustive. Other factors that could adversely affect the Company's business and prospects are described in the Company's filings with the Securities and Exchange Commission. Hologic expressly disclaims any obligation or undertaking to release publicly any updates or revisions to the data or statements presented herein to reflect any change in the Company's expectations or any change in events, conditions or circumstances on which any such data or statements are based. Contact:  

Deborah GordonVice President, Investor RelationsHologic, Inc.Deborah.gordon@hologic.com(781) 999-7716
'/>"/>

SOURCE Hologic, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. FDA Approves Drug to Reduce Risk of Preterm Birth in At-Risk Pregnant Women
2. FDA Approves Makena™, the First and Only Treatment to Reduce the Risk of Preterm Birth in Women With a Singleton Pregnancy Who Have a History of Singleton Spontaneous Preterm Birth
3. FDA Approves Viibryd to Treat Major Depressive Disorder
4. FDA Approves Head Lice Treatment for Children and Adults
5. FDA Approves Opioid Analgesic to Help Cancer Patients Manage Pain
6. VIDEO from Endo Pharmaceuticals Available on thenewsmarket.com: FDA Approves New Treatment for Low Testosterone
7. FDA Approves New Dosage Strength for INTELENCE®
8. U.S. FDA Approves Second Bayer Oral Contraceptive That Also Raises Folate Levels
9. FDA Approves PREZISTA®/ritonavir Once-Daily Dosing for HIV-1 Treatment-Experienced Adults With No Darunavir Resistance-Associated Mutations
10. FDA Approves New Manufacturing Facility for Collagenase SANTYL® Ointment
11. Vermillion Reappoints Three Directors, Approves a New Stock Incentive Plan, and Ratifies PricewaterhouseCoopers LLP as Its Accounting Firm
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/17/2017)... NEW YORK , Feb. 17, 2017   ... other side effects allegedly associated with use of the ... Philadelphia Court of Common Pleas, ... a mass tort program. According to a notice posted ... scheduled to convene a meeting on March 9, 2017 ...
(Date:2/17/2017)... 17, 2017  Featuring new and ... the  2017 HIMSS Conference & Exhibition (HIMSS17 ),  Royal ... global leader in health technology,  will ... population health management, acute healthcare informatics ... a highly secure, cloud-based ecosystem. Visitors ...
(Date:2/17/2017)... -- Noble Capital Markets announced today that it has initiated ... EPIX ). The report was issued by Noble,s Head ... ESSA Pharmaceuticals is a clinical stage biopharmaceutical company ... lead compound EPI-506, is a small molecule oral drug ... receptor, thereby has potential to overcome some of the ...
Breaking Medicine Technology:
(Date:2/17/2017)... ... February 17, 2017 , ... Wells Pharmacy ... electronic prescribing of controlled and non-controlled substances plus the ability to manage orders ... the United States now accept electronic prescriptions, according to the Office of the ...
(Date:2/17/2017)... ... February 17, 2017 , ... ... Dr. Carol Francis' goals for each and every seminar, session and class ... will demonstrate five different brainwave tools which help energize creativity, focus mental functions, ...
(Date:2/17/2017)... ... February 17, 2017 , ... Access today ... Exhibition in Orlando, Fla., February 19-23. Visitors to the company’s booth (#1778) will ... used electronic patient signatures solution in healthcare . , Since it first ...
(Date:2/17/2017)... ... February 17, 2017 , ... ... executives and focusing on all facets of clinical trial planning and management. Pharmica ... patient engagement, and more. In addition, attendees stopping by Pharmica’s booth were able ...
(Date:2/17/2017)... ... February 17, 2017 , ... Like most hospitals across the nation, ... large part by the Hospital Readmission Reduction Program (HRRP), the return of a patient ... for hospitals across the nation. While many providers are struggling to leverage limited resources ...
Breaking Medicine News(10 mins):